Drugs / TOREFORANT
last change Mar 2016 re-read 2 minutes ago

TOREFORANT

Small molecule targets HRH4 via inhibition

Developed for
rheumatoid arthritis · asthma · psoriasis
Investigated by
Janssen Research & Development, LLC · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Trials 10 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT01863784 Apr → Nov 2013 Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT01690286 Oct → Dec 2012 Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT01970020 Oct → Dec 2012 Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT01442532 Sep 2011 → Jul 2012 Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT01450982 Jun → Oct 2011 rheumatoid arthritis Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 25 trials
Phase 2 NCT02295865 Nov 2014 → Mar 2016 psoriasis Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT01823016 Sep 2013 → Jul 2015 asthma Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT01862224 Jul 2013 → Jul 2014 rheumatoid arthritis Janssen Research & Development, LLC Terminated No outcome recorded
Phase 2 NCT01679951 Oct 2012 → Apr 2014 rheumatoid arthritis Janssen Research & Development, LLC Terminated No outcome recorded
Phase 2 NCT00941707 Feb → Nov 2010 rheumatoid arthritis Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Terminated No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as TOREFORANT ChEMBL registry synonym — accepted as the source's own label CHEMBL3301609
Known as JNJ-38518168 “The purpose of this study is to evaluate the efficacy, tolerability and safety of JNJ-38518168 compared with placebo” NCT00941707
10

NCT01823016

NCT02295865

NCT01970020

NCT01863784

NCT01690286

NCT00941707

NCT01442532

NCT01862224

NCT01450982

NCT01679951

Known as JNJ-38518168 HEMITARTRATE ChEMBL registry synonym — accepted as the source's own label CHEMBL3301609
Known as TOREFORANT TARTRATE ChEMBL registry synonym — accepted as the source's own label CHEMBL3301609
Action Inhibit “Histamine H4 receptor antagonist” CHEMBL3301609
Modality Small molecule CHEMBL3301609
Route Oral “JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.” NCT00941707
Target HRH4 “Histamine H4 receptor antagonist” CHEMBL3301609